Broadening Our Developmental Pipeline
Beyond our late-stage Plinabulin studies, BeyondSpring has embarked on a broad immuno-oncology strategy, leveraging additional potential applications for Plinabulin discovered through our further discovery of Plinabulin’s mechanism as a tumor micro-environment-targeting agent.
Plinabulin Triple Combination:
Novel Product Candidates:
BPI-002: Oral CTLA4 Inhibitor-like molecule
BPI-004: Neo-Antigen Formation to turn ‘cold’ tumors into ‘hot’
BeyondSpring has obtained an exclusive license from University of Washington for a platform technology focused on the ubiquitin ligase protein to degrade a multitude of oncogenes and targets that had been previously undruggable using small molecule “molecular glue” compounds. Through this collaboration, the Company plans to use its combined resources to screen and optimize potential solutions and use oncology clinical expertise to quickly advance identified candidate into the clinic for testing. Dr. Lan Huang, co-founder of BeyondSpring and Dr. Ning Zheng, HHMI investigator from University of Washington, are the pioneers who solved the first structures of E3 ligase classes, which are key enzymes to target in this platform. Revlimid, a similar kind of “molecular glue,” is a marketed product that has generated more than $7 billion dollars in peak annual sales.